Trigr gets rights to ABL's bispecific antibody

ABL Bio Inc. (KOSDAQ:298380) granted Trigr Therapeutics Inc. (Irvine, Calif.) exclusive rights to TR009 (formerly ABL001, NOV1501), a bispecific antibody targeting δ like canonical Notch ligand 4 (DLL4) and VEGF. Trigr gets worldwide development and commercialization rights excluding South Korea for oncology indications, as well as worldwide development and commercialization rights excluding South Korea and Japan for ophthalmology indications.

ABL will receive $5 million up front and is eligible for up to $405 million in milestones and royalties on oncology sales outside of South Korea and up to $185 million in milestones and royalties in ophthalmology sales outside of South Korea and Japan...